# Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

> **NCT05198843** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Inflammatory Carcinoma

## Interventions

- **DRUG:** Dasatinib
- **DIETARY_SUPPLEMENT:** Icosapent Ethyl

## Key facts

- **NCT ID:** NCT05198843
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-08
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-20
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Other - Poor accrual
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198843, "Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05198843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*